Development of growth hormone secretagogues.
暂无分享,去创建一个
[1] S. Toler,et al. Preclinical pharmacology of CP-424,391, and orally active pyrazolinone-piperidine growth hormone secretagogue , 2001, Endocrine.
[2] D. Taub,et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. , 2004, The Journal of clinical investigation.
[3] D. Macneil,et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. , 2004, Endocrinology.
[4] C. Zetterberg,et al. The Effects of MK‐0677, an Oral Growth Hormone Secretagogue, in Patients with Hip Fracture , 2004, Journal of the American Geriatrics Society.
[5] Hui Zheng,et al. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[6] F. Casanueva,et al. Agonist-Specific Coupling of Growth Hormone Secretagogue Receptor Type 1a to Different Intracellular Signaling Systems , 2004, Neuroendocrinology.
[7] Yuxiang Sun,et al. Deletion of Ghrelin Impairs neither Growth nor Appetite , 2003, Molecular and Cellular Biology.
[8] Michael Esterman,et al. The Distribution and Mechanism of Action of Ghrelin in the CNS Demonstrates a Novel Hypothalamic Circuit Regulating Energy Homeostasis , 2003, Neuron.
[9] S. Ljunghall,et al. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.
[10] D. Galimberti,et al. Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. , 2002, The Journal of endocrinology.
[11] D. Johnston,et al. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. , 2002, Journal of medicinal chemistry.
[12] Roy G. Smith,et al. Huffington Center on Aging , 2002, Experimental Gerontology.
[13] K. Raun,et al. The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency. , 2002, European journal of medicinal chemistry.
[14] M. Schambelan,et al. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone , 2002, AIDS.
[15] E. Dellinger,et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. , 2002, The New England journal of medicine.
[16] M. Low,et al. Ghrelin gene expression is age-dependent and influenced by gender and the level of circulating IGF-I , 2002, Molecular and Cellular Endocrinology.
[17] J. Nagamine,et al. Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686. , 2001, The Journal of endocrinology.
[18] M. Bednarek,et al. 1H NMR structural analysis of human ghrelin and its six truncated analogs. , 2001, Biopolymers.
[19] G. Frost,et al. Ghrelin enhances appetite and increases food intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.
[20] R. Batterham,et al. Ghrelin causes hyperphagia and obesity in rats. , 2001, Diabetes.
[21] K. Moriyama,et al. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. , 2001, The Journal of clinical endocrinology and metabolism.
[22] K. Raun,et al. Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. , 2001, Bioorganic & medicinal chemistry letters.
[23] M. Suchard,et al. Synchronicity of frequently sampled thyrotropin (TSH) and leptin concentrations in healthy adults and leptin-deficient subjects: evidence for possible partial TSH regulation by leptin in humans. , 2001, The Journal of clinical endocrinology and metabolism.
[24] R. Nargund,et al. Immune Enhancing Effect of a Growth Hormone Secretagogue , 2001, The Journal of Immunology.
[25] T. Schnitzer,et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. , 2001, The Journal of clinical endocrinology and metabolism.
[26] M. M. Ilondo,et al. The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects. , 2001, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[27] M. Nakazato,et al. A role for ghrelin in the central regulation of feeding , 2001, Nature.
[28] S. Toler,et al. Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine [correction of pyrazolidinone-piperidine] growth hormone secretagogue. , 2001, Endocrine.
[29] F. Casanueva,et al. Ghrelin-induced growth hormone secretion in humans. , 2000, European journal of endocrinology.
[30] A. Pomés,et al. Adenosine: A partial agonist of the growth hormone secretagogue receptor. , 2000, Biochemical and biophysical research communications.
[31] M. Papotti,et al. Growth hormone secretagogue binding sites in peripheral human tissues. , 2000, The Journal of clinical endocrinology and metabolism.
[32] L. Thim,et al. Adenosine is an agonist of the growth hormone secretagogue receptor. , 2000, Endocrinology.
[33] K. Raun,et al. New highly potent dipeptidic growth hormone secretagogues with low molecular weight. , 2000, European journal of medicinal chemistry.
[34] Dickson,et al. Growth Hormone Secretagogue Activation of the Arcuate Nucleus and Brainstem Occurs Via a Non‐Noradrenergic Pathway , 2000, Journal of neuroendocrinology.
[35] J. Sturis,et al. High-frequency oscillations in circulating amylin concentrations in healthy humans. , 2000, American journal of physiology. Endocrinology and metabolism.
[36] G. Leng,et al. Central Actions of Peptide and Nonpeptide Growth Hormone Secretagogues , 2000 .
[37] A. Howard,et al. Ligand activation domain of human orphan growth hormone (GH) secretagogue receptor (GHS-R) conserved from Pufferfish to humans. , 2000, Molecular endocrinology.
[38] M. Nakazato,et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.
[39] J. Rømer,et al. Co-Localization of Growth Hormone Secretagogue Receptor and NPY mRNA in the Arcuate Nucleus of the Rat , 1999, Neuroendocrinology.
[40] T. McDonald,et al. Administration of a nonpeptidyl growth hormone secretagogue, L-163, 255, changes somatostatin pattern, but has no effect on patterns of growth hormone-releasing factor in the hypophyseal-portal circulation of the conscious pig. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[41] K. Raun,et al. Pharmacological characterisation of a new oral GH secretagogue, NN703. , 1999, European journal of endocrinology.
[42] B. S. Hansen,et al. New growth hormone secretagogues: C-terminal modified sulfonamide-analogues of NN703. , 1999, Bioorganic & medicinal chemistry letters.
[43] Roy G. Smith,et al. A New Orphan Receptor Involved in Pulsatile Growth Hormone Release , 1999, Trends in Endocrinology & Metabolism.
[44] R. Ross. Growth Hormone Secretagogues in Clinical Practice , 1998 .
[45] R G Smith,et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. , 1998, Science.
[46] A. Beaudet,et al. Expression of growth hormone secretagogue-receptors by growth hormone-releasing hormone neurons in the mediobasal hypothalamus. , 1998, Endocrinology.
[47] K. Raun,et al. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. , 1998, Journal of medicinal chemistry.
[48] B H Arison,et al. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[49] A. Patchett,et al. Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential. , 1998, Journal of medicinal chemistry.
[50] D. Underwood,et al. Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues. , 1998, Molecular endocrinology.
[51] A. Patchett,et al. Synthesis and biological activities of phenyl piperazine-based peptidomimetic growth hormone secretagogues. , 1998, Bioorganic & medicinal chemistry letters.
[52] D. Longo,et al. Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin‐like growth factor in HIV‐infected patients , 1998, AIDS.
[53] R. DeVita,et al. A potent, orally bioavailable benzazepinone growth hormone secretagogue. , 1998, Journal of medicinal chemistry.
[54] Johannes D. Veldhuis,et al. Synchronicity of frequently sampled, 24-h concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[55] L. Lönn,et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. , 1998, The Journal of clinical endocrinology and metabolism.
[56] D. Clemmons,et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. , 1998, The Journal of clinical endocrinology and metabolism.
[57] A. Patchett,et al. Potent 3-spiropiperidine growth hormone secretagogues. , 1998, Bioorganic & Medicinal Chemistry Letters.
[58] N. Berman,et al. Counterregulatory hormones oscillate during steady-state hypoglycemia. , 1998, The American journal of physiology.
[59] K. Madsen,et al. Aminomethylthiophene‐2‐carboxylic Acids as Dipeptide Mimetic in New Growth Hormone Secretagogues. , 1997 .
[60] P. Bergsten,et al. Pulsatile insulin release from pancreatic islets with nonoscillatory elevation of cytoplasmic Ca2+. , 1997, The Journal of clinical investigation.
[61] Roy G. Smith,et al. Peptidomimetic regulation of growth hormone secretion. , 1997, Endocrine reviews.
[62] Roy G. Smith,et al. Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons. , 1997, Molecular endocrinology.
[63] T. Hansen,et al. Investigation of Bioisosteres of the Growth Hormone Secretagogue L‐692, 429. , 1997 .
[64] Roy G. Smith,et al. The design and synthesis of orally active short duration spiroindane growth hormone secretagogues , 1997 .
[65] M. K. James,et al. Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. , 1997, Journal of medicinal chemistry.
[66] Roy G. Smith,et al. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. , 1997, Brain research. Molecular brain research.
[67] R. Lieber,et al. Growth hormone secretagogue increases muscle strength during remobilization after canine hindlimb immobilization , 1997, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[68] T. Hansen,et al. INVESTIGATION OF BIOISOSTERS OF THE GROWTH HORMONE SECRETAGOGUE L-692,429. , 1997 .
[69] S. Schneider,et al. Effect of obesity and feeding on the growth hormone (GH) response to the GH secretagogue L-692,429 in young men. , 1997, The Journal of clinical endocrinology and metabolism.
[70] M. Phillips,et al. Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. , 1997, Molecular endocrinology.
[71] R. Clark,et al. The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. , 1997, Endocrine reviews.
[72] D. Krupa,et al. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles. , 1997, The Journal of endocrinology.
[73] S. Dickson,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society Induction of c-fos Messenger Ribonucleic Acid in Neuropeptide Y and Growth Hormone (GH)-Releasing Factor Neurons in the Rat Arcuate Nucleus Following Systemic Injection of the GH Secretagogue, GH , 2022 .
[74] D. Underwood,et al. Structural Requirements for the Activation of the Human Growth Hormone Secretagogue Receptor by Peptide and Nonpeptide Secretagogues , 1997 .
[75] D. Krupa,et al. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. , 1996, Endocrinology.
[76] E. van Cauter,et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. , 1996, The Journal of clinical endocrinology and metabolism.
[77] R. Dyball,et al. Retrogradely labelled neurosecretory neurones of the rat hypothalamic arcuate nucleus express Fos protein following systemic injection of GH-releasing peptide-6. , 1996, The Journal of endocrinology.
[78] Patrick R. Griffin,et al. A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release , 1996, Science.
[79] M. Thorner,et al. Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic, L-692,429, in older adults--a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.
[80] I. Clarke,et al. Growth hormone-releasing hormone and somatostatin concentrations in the hypophysial portal blood of conscious sheep during the infusion of growth hormone-releasing peptide-6. , 1996, Domestic animal endocrinology.
[81] L. V. D. van der Ploeg,et al. Development of a high specific activity sulfur-35-labeled sulfonamide radioligand that allowed the identification of a new growth hormone secretagogue receptor. , 1996, Journal of medicinal chemistry.
[82] S. Pong,et al. Identification of a new G-protein-linked receptor for growth hormone secretagogues. , 1996, Molecular endocrinology.
[83] I. Robinson,et al. Mechanism of Action of GHRP-6 and Nonpeptidyl Growth Hormone Secretagogues , 1996 .
[84] J. P. Arena,et al. Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. , 1996, Recent progress in hormone research.
[85] D. Johnston,et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[86] I. Robinson,et al. Consistent GH responses to repeated injection of GH-releasing hexapeptide (GHRP-6) and the non-peptide GH secretagogue, L-692,585. , 1995, The Journal of endocrinology.
[87] W. Greenlee,et al. Non-peptide Angiotensin Agonist , 1995, The Journal of Biological Chemistry.
[88] Joshua R. Smith,et al. Design and pharmacology of peptide mimetics. , 1995, Advances in pharmacology.
[89] J. Taylor,et al. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles. , 1994, The Journal of endocrinology.
[90] V. Lenaerts,et al. Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep. , 1994, Endocrinology.
[91] D. Taub,et al. Growth hormone promotes human T cell adhesion and migration to both human and murine matrix proteins in vitro and directly promotes xenogeneic engraftment. , 1994, The Journal of clinical investigation.
[92] J. Taylor,et al. Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue, in beagles. , 1994, Endocrinology.
[93] S. Pong,et al. A nonpeptidyl growth hormone secretagogue. , 1993, Science.
[94] I. Robinson,et al. Systemic administration of growth hormone-releasing peptide activates hypothalamic arcuate neurons , 1993, Neuroscience.
[95] D. Longo,et al. Human growth hormone promotes engraftment of murine or human T cells in severe combined immunodeficient mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[96] C. Bowers,et al. The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. , 1992, The Journal of clinical endocrinology and metabolism.
[97] R. Smith,et al. Evidence for a role of protein kinase-C in His-D-Trp-Ala-Trp-D-Phe-Lys-NH2-induced growth hormone release from rat primary pituitary cells. , 1991, Endocrinology.
[98] R. Campbell,et al. GRF analogs and fragments: Correlation between receptor binding, activity and structure , 1991, Peptides.
[99] R. Smith,et al. Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 stimulate growth hormone release through distinct receptor sites. , 1991, The Journal of endocrinology.
[100] E. Eldrup,et al. EFFECT OF DOPAMINE AND A DOPAMINE D‐1 RECEPTOR AGONIST ON PULSATILE THYROTROPHIN SECRETION IN NORMAL WOMEN , 1990, Clinical endocrinology.
[101] E. Tadamura,et al. Episodic fluctuation in serum intact parathyroid hormone concentration in men. , 1990, The Journal of clinical endocrinology and metabolism.
[102] E. Convey,et al. The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture. , 1989, Endocrinology.
[103] J. Deslypere,et al. Influence of antiopioids on luteinizing hormone pulsatility in aging men. , 1989, The Journal of clinical endocrinology and metabolism.
[104] B. E. Evans,et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of medicinal chemistry.
[105] D. Clemmons,et al. Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis, and body composition. , 1988, The Journal of clinical endocrinology and metabolism.
[106] J. Butler,et al. Neuroendocrine-gonadal axis in men: frequent sampling of LH, FSH, and testosterone. , 1988, The American journal of physiology.
[107] K. Alberti,et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. , 1988, The Journal of clinical investigation.
[108] A. Rogol,et al. Operating characteristics of the male hypothalamo-pituitary-gonadal axis: pulsatile release of testosterone and follicle-stimulating hormone and their temporal coupling with luteinizing hormone. , 1987, The Journal of clinical endocrinology and metabolism.
[109] E. Cauter,et al. Control of circadian and episodic variations of adrenal androgens secretion in man , 1987, Journal of endocrinological investigation.
[110] A. Rogol,et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. , 1987, The Journal of clinical endocrinology and metabolism.
[111] S. Winters,et al. Testosterone and estradiol are co-secreted episodically by the human testis. , 1986, The Journal of clinical investigation.
[112] Manson Jm,et al. Positive nitrogen balance with human growth hormone and hypocaloric intravenous feeding. , 1986 .
[113] R L Landau,et al. The effect of dexamethasone on the 24-hour profiles of adrenocorticotropin and cortisol in Cushing's syndrome. , 1985, The Journal of clinical endocrinology and metabolism.
[114] N. Ueno,et al. Synthesis and invitro bioactivity of C-terminal deleted analogs of human growth hormone-releasing factor , 1984 .
[115] F. Momany,et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. , 1984, Endocrinology.
[116] U. Goebelsmann,et al. Effect of estradiol on plasma melatonin levels , 1984, Journal of endocrinological investigation.
[117] N. Ling,et al. Synthesis and in vitro bioactivity of C-terminal deleted analogs of human growth hormone-releasing factor. , 1984, Biochemical and biophysical research communications.
[118] D. Clemmons,et al. Dietary components that regulate serum somatomedin-C concentrations in humans. , 1983, The Journal of clinical investigation.
[119] S. Winters,et al. Episodic luteinizing hormone (LH) secretion and the response of LH and follicle-stimulating hormone to LH-releasing hormone in aged men: evidence for coexistent primary testicular insufficiency and an impairment in gonadotropin secretion. , 1982, The Journal of clinical endocrinology and metabolism.
[120] F. Momany,et al. Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. , 1980, Endocrinology.
[121] J. F. Miranda,et al. The Pharmacon-Receptor-Effector Concept , 1979 .
[122] D. Fukushima,et al. Studies of the diurnal pattern of plasma corticosteroids and gonadotropins in two cases of feminizing adrenal carcinoma: measurements of estrogen and corticosteroid production. , 1977, The Journal of clinical endocrinology and metabolism.
[123] R. Rosenfield,et al. Small diurnal and episodic fluctuations of the plasma free testosterone level in normal women. , 1974, American journal of obstetrics and gynecology.
[124] S. Yen,et al. Circulating prolactin levels during the menstrual cycle: episodic release and diurnal variation. , 1973, American journal of obstetrics and gynecology.
[125] F. H. Tyler,et al. Simultaneous measurement of multiple plasma steroids by radioimmunoassay demonstrating episodic secretion. , 1973, The Journal of clinical endocrinology and metabolism.